Collegium (COLL) Xtampza ER Sales More than Double Expectations - William Blair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 8, 2017 4:01 PM ESTXtampza® ER prescriptions grow by 49% in the third quarterFDA Approval of sNDA, including Comparative OxyContin DataStrong balance sheet provides cash runway into mid-2019 Conference call scheduled for today at 4:30 p.m. ET
CANTON, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2017 and provided a corporate update.Â
We are encouraged by the continued adoption of Xtampza ER with consistent prescription growth during the third quarter, said Michael... More
